{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:57Z","timestamp":1758845937819,"version":"3.44.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04466-6","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:57:11Z","timestamp":1744207031000},"page":"3181-3190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Weijie","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiduo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangnan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"4466_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer J Clinic. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA a Cancer J Clinic"},{"issue":"2","key":"4466_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nucmedbio.2013.11.006","volume":"41","author":"K Durkan","year":"2014","unstructured":"Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP et al (2014) A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] \u03b1v\u03b23\/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol 41(2):133\u2013139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.11.006","journal-title":"Nucl Med Biol"},{"key":"4466_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update part 1: screening, diagnosis, and local treatment with curative intent. European Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"European Urol"},{"key":"4466_CR4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2004.0021","author":"NCC Network","year":"2004","unstructured":"Network NCC (2004) Prostate cancer NCCN clinical practice guidelines in oncology. J Nat Comprehen Cancer Net\u202f: JNCCN. https:\/\/doi.org\/10.6004\/jnccn.2004.0021","journal-title":"J Nat Comprehen Cancer Net : JNCCN."},{"issue":"3","key":"4466_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1113162","volume":"367","author":"TJ Wilt","year":"2012","unstructured":"Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203\u2013213. https:\/\/doi.org\/10.1056\/NEJMoa1113162","journal-title":"N Engl J Med"},{"issue":"1","key":"4466_CR6","doi-asserted-by":"publisher","first-page":"15452","DOI":"10.1038\/s41598-022-19700-9","volume":"12","author":"CH Song","year":"2022","unstructured":"Song CH, Kim K, Kang E, Jeong B, Lee MS, Jung J et al (2022) Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand, (177)Lu-DOTA-PSMA-GUL, in rats by using LC-MS\/MS. Sci Rep 12(1):15452. https:\/\/doi.org\/10.1038\/s41598-022-19700-9","journal-title":"Sci Rep"},{"key":"4466_CR7","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/ott.S147168","volume":"11","author":"JT Chong","year":"2018","unstructured":"Chong JT, Oh WK, Liaw BC (2018) Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. Onco Targets Ther 11:2141\u20132147. https:\/\/doi.org\/10.2147\/ott.S147168","journal-title":"Onco Targets Ther"},{"issue":"10437","key":"4466_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/s0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA et al (2024) The lancet commission on prostate cancer: planning for the surge in cases. Lancet (London, England) 403(10437):1683\u20131722. https:\/\/doi.org\/10.1016\/s0140-6736(24)00651-2","journal-title":"Lancet (London, England)"},{"key":"4466_CR9","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.01.04","author":"National Health Commission of PRC","year":"2019","unstructured":"National Health Commission of PRC (2019) Chinese guidelines for diagnosis and treatment of prostate cancer. Chinese J Cancer Res = Chung-kuo yen cheng yen chiu. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.01.04","journal-title":"Chinese J Cancer Res = Chung-kuo yen cheng yen chiu"},{"issue":"10","key":"4466_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1311593","volume":"370","author":"A Bill-Axelson","year":"2014","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932\u2013942. https:\/\/doi.org\/10.1056\/NEJMoa1311593","journal-title":"N Engl J Med"},{"issue":"16","key":"4466_CR11","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/jnci\/djn255","volume":"100","author":"A Bill-Axelson","year":"2008","unstructured":"Bill-Axelson A, Holmberg L, Fil\u00e9n F, Ruutu M, Garmo H, Busch C et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144\u20131154. https:\/\/doi.org\/10.1093\/jnci\/djn255","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"4466_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","volume":"364","author":"A Bill-Axelson","year":"2011","unstructured":"Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa1011967","journal-title":"N Engl J Med"},{"issue":"6","key":"4466_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","volume":"77","author":"TJ Wilt","year":"2020","unstructured":"Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ et al (2020) Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol 77(6):713\u2013724. https:\/\/doi.org\/10.1016\/j.eururo.2020.02.009","journal-title":"Eur Urol"},{"issue":"9","key":"4466_CR14","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s00277-024-05894-7","volume":"103","author":"J Yan","year":"2024","unstructured":"Yan J, Hammami MB, Wei JX, Shah N, Goldfinger M, Mantzaris I et al (2024) Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database. Ann Hematol 103(9):3543\u20133551. https:\/\/doi.org\/10.1007\/s00277-024-05894-7","journal-title":"Ann Hematol"},{"issue":"1","key":"4466_CR15","doi-asserted-by":"publisher","first-page":"2304099","DOI":"10.1080\/0886022x.2024.2304099","volume":"46","author":"L Cheng","year":"2024","unstructured":"Cheng L, Jia HM, Zheng X, Jiang YJ, Xin X, Li WX (2024) Association between the levels of urinary cell cycle biomarkers and non-recovery of renal function among critically ill geriatric patients with acute kidney injury. Ren Fail 46(1):2304099. https:\/\/doi.org\/10.1080\/0886022x.2024.2304099","journal-title":"Ren Fail"},{"issue":"11","key":"4466_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969\u2013974. https:\/\/doi.org\/10.1001\/jama.280.11.969","journal-title":"JAMA"},{"issue":"15","key":"4466_CR17","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/0008-5472.Can-21-2978","volume":"82","author":"M Wang","year":"2022","unstructured":"Wang M, Long Q (2022) Addressing common misuses and pitfalls of p values in biomedical research. Can Res 82(15):2674\u20132677. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-2978","journal-title":"Can Res"},{"issue":"1","key":"4466_CR18","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1080\/10717544.2022.2110998","volume":"29","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Lu T, Luo J, Xue H (2022) Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. Drug Delivery 29(1):2705\u20132712. https:\/\/doi.org\/10.1080\/10717544.2022.2110998","journal-title":"Drug Delivery"},{"key":"4466_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3503","volume":"371","author":"CG Mazariego","year":"2020","unstructured":"Mazariego CG, Egger S, King MT, Juraskova I, Woo H, Berry M et al (2020) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ (Clinical research ed) 371:m3503. https:\/\/doi.org\/10.1136\/bmj.m3503","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"4466_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cam4.557","volume":"5","author":"YW Yang","year":"2016","unstructured":"Yang YW, Lee SS, Chen CC, Liu HH, Tsai TH, Lin TH et al (2016) CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy. Cancer Med 5(1):3\u20138. https:\/\/doi.org\/10.1002\/cam4.557","journal-title":"Cancer Med"},{"issue":"17","key":"4466_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"issue":"1","key":"4466_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12911-020-01355-z","volume":"20","author":"K Nakayama","year":"2020","unstructured":"Nakayama K, Osaka W, Matsubara N, Takeuchi T, Toyoda M, Ohtake N et al (2020) Shared decision making, physicians\u2019 explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients. BMC Med Inform Decis Mak 20(1):334. https:\/\/doi.org\/10.1186\/s12911-020-01355-z","journal-title":"BMC Med Inform Decis Mak"},{"key":"4466_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3712","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the us preventive services task force. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.3712","journal-title":"JAMA"},{"key":"4466_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/pap.0000000000000400","author":"GP Paner","year":"2023","unstructured":"Paner GP, Zhou M, Simko JP, Eggener SE, van der Kwast T (2023) Renaming grade group 1 prostate \u201ccancer\u201d from a pathology perspective: a call for multidisciplinary discussion. Adv Anat Pathol. https:\/\/doi.org\/10.1097\/pap.0000000000000400","journal-title":"Adv Anat Pathol"},{"key":"4466_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctro.2018.05.001","volume":"11","author":"LF van Dessel","year":"2018","unstructured":"van Dessel LF, Reuvers SHM, Bangma CH, Aluwini S (2018) Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes. Clinical and translational radiation oncology 11:26\u201332. https:\/\/doi.org\/10.1016\/j.ctro.2018.05.001","journal-title":"Clinical and translational radiation oncology"},{"key":"4466_CR26","doi-asserted-by":"publisher","first-page":"11453","DOI":"10.2147\/cmar.S273394","volume":"12","author":"F Jiang","year":"2020","unstructured":"Jiang F, Wu P (2020) Regulating DSC2 expression affects the proliferation and apoptosis of prostate cancer cells. Cancer Manage Res 12:11453\u201311462. https:\/\/doi.org\/10.2147\/cmar.S273394","journal-title":"Cancer Manage Res"},{"key":"4466_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00814","author":"SC Wang","year":"2020","unstructured":"Wang SC, Ting WC, Chang YC, Yang CC, Lin LC, Ho HW et al (2020) Whole pelvic radiotherapy with stereotactic body radiotherapy boost vs conventionally fractionated radiotherapy for patients with high or very high-risk prostate cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00814","journal-title":"Front Oncol"},{"issue":"13","key":"4466_CR28","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1245\/s10434-024-16258-w","volume":"31","author":"C Siech","year":"2024","unstructured":"Siech C, de Angelis M, Di Bello F, Rodriguez Pe\u00f1aranda N, Goyal JA, Tian Z et al (2024) Adult prostate sarcoma: demographics, treatment patterns, and survival. Ann Surg Oncol 31(13):8993\u20139001. https:\/\/doi.org\/10.1245\/s10434-024-16258-w","journal-title":"Ann Surg Oncol"},{"key":"4466_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00866-4","author":"C Siech","year":"2024","unstructured":"Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Pe\u00f1aranda N, Goyal JA et al (2024) Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-024-00866-4","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4466_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35323","author":"C Siech","year":"2024","unstructured":"Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Pe\u00f1aranda N, Goyal JA et al (2024) Life expectancy in rare histological prostate cancer subtypes. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.35323","journal-title":"Int J Cancer"},{"issue":"8","key":"4466_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pros.24689","volume":"84","author":"F Di Bello","year":"2024","unstructured":"Di Bello F, Baudo A, de Angelis M, Jannello LMI, Siech C, Tian Z et al (2024) Other-cause mortality in incidental prostate cancer. Prostate 84(8):731\u2013737. https:\/\/doi.org\/10.1002\/pros.24689","journal-title":"Prostate"},{"issue":"2","key":"4466_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/pros.24816","volume":"85","author":"F Di Bello","year":"2025","unstructured":"Di Bello F, Jannello LMI, Baudo A, de Angelis M, Siech C, Tian Z et al (2025) Life expectancy in high-grade incidental prostate cancer patients versus population-based controls according to treatment type. Prostate 85(2):191\u2013197. https:\/\/doi.org\/10.1002\/pros.24816","journal-title":"Prostate"},{"key":"4466_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.278","author":"F Di Bello","year":"2025","unstructured":"Di Bello F, Scheipner L, Baudo A, de Angelis M, Jannello LMI, Siech C et al (2025) Cancer-specific mortality after radical prostatectomy versus radiotherapy in incidental prostate cancer. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.278","journal-title":"Urol Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04466-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04466-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04466-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:00:19Z","timestamp":1758808819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04466-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4466"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04466-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}